What’s Happening to the Share Price of Pharmaxis Ltd?

financial system thinking

What does Pharmaxis Ltd do?

Pharmaxis Ltd [ASX:PXS] is a research based pharmaceutical company with a portfolio of products at various stages of development and approval.
It has Bronchitol for cystic fibrosis marketed in Europe and Australia. A clinical trial is underway aiming to secure approval for Bronchitol in the US.
The drug Aridol, for the assessment of asthma is approved and sold in Europe, Australia and Asia.
The company also has other products in the pipeline, targeting liver related conditions, pulmonary fibrosis and some cancers.
That’s interesting, but what is the chart telling us?

What does the chart look like?

I find it helpful to bring up a chart. Here’s the daily chart of PXS.


Source: STEX

Almost a month ago the share price gapped up on news of the company completing its restructure program and announcing a new focus on partnering to de-risk projects and generate increased revenues.
Since then the gap has not been filled and the stock has been trading in a very narrow range. A strong break either way will tell us if the new focus on partnering is successful.

Are PXS shares a buy?

Well you could let the market tell you that. So far it is trading in a very narrow range. While the gap up does not fill, one could keep an eye on PXS just to see how things progress.
You just need a little charting knowledge to know how to proceed. You can get that chart reading knowledge here. You remain at a substantial investment disadvantage without it.

Terence Duffy,
Research Analyst, Cycles, Trends and Forecasts

Join Markets and Money on Google+

Leave a Reply

Be the First to Comment!

Notify of
Letters will be edited for clarity, punctuation, spelling and length. Abusive or off-topic comments will not be posted. We will not post all comments.
If you would prefer to email the editor, you can do so by sending an email to letters@marketsandmoney.com.au